Business
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company$19 million financings to advance lead clinical candidate
About this update from Pulmatrix, Inc.
[{"type":"text","content":"Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company$19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related diseaseFRAMINGHAM, Mass. and HOUSTON, March 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) (\"Pulmatrix\") and Eos SENOLYTIX, Inc. (\"Eos\"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, today jointly announced a definitive merger agreement under which Pulmatrix will acquire Eos (the \"Merger\"). Upon completion of the Merger, the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker symbol \"EOSX.\"\n \n \n \n \n \n \n \nIn connection with the Merger, Eos and Pulmatrix have entered into definitive agreements for concurrent private financings of $19 million in aggregate gross proceeds (the \"Financings\"), including a $1 million investment in Pulmatrix from RCM Eos PIPE HOLDINGS LLC, and a bridge component for Eos from RCM Eos Holdings, LLC, both managed by Rapha Capital Management, LLC. The net proceeds are expected to support advancement of Eos's proprietary MitoXcel™ platform, including its lead clinical candidate, PTC-2105, for sarcopenia and sarcopenic obesity. The proposed Merger has been unanimously approved by the boards of directors of both companies and is currently expected to close in mid-2026, subject to customary closing conditions, including approval by the stockholders of each company and the effectiveness of a registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission. Following the closing of the proposed Merger and payment of all placement and M&A advisory fees, the pre-Merger Pulmatrix stockholders are expected to own approximately 6% of the combined company, while pre-Merger Eos stockholders, including investors participating in the Financings and holders of shares issued in payment of placement agent and M&A advisory fees, are expected to own approximately 94%.Eos SENOLYTIX Background and HighlightsThe combined company will be positioned as a leader in the emerging field of gerotherapeutics — medicines that target the root biological mechanisms of aging to improve healthspan. Strong scientific evidence shows that obesity is associated with aging,...